A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

• Documented diagnosis of MM based on standard International Myeloma Working Group (IMWG) criteria

• Evidence of progressive disease based on investigators determination of response byIMWG criteria on or after their last dosing regimen

• Prior BCMA ADC or CAR-T Cohort: participants who have received a BCMA-targeted CAR-Tor ADC therapy and are triple-class relapsed or refractory

• Prior BCMA Bispecific Cohort: participants who have received a BCMA-targetingT-cell-dependent bispecific (TDB) antibody and are triple-class relapsed orrefractory

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Life expectancy is at least 12 weeks

• Agreement to protocol-specified assessments, including bone marrow biopsy andaspirate samples as detailed in the protocol

• Resolution of AEs from prior anti-cancer therapy to Grade =< 1

• For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatmentperiod and for at least 5 months after the final dose of cevostamab and for 3 monthsafter the last dose of tocilizumab was administered

• For male participants: agreement to remain abstinent (refrain from heterosexualintercourse) or use a condom, and agree to refrain from donating sperm during thetreatment period and for at least 2 months after the final dose of tocilizumab (ifapplicable) to avoid exposing the embryo

Exclusion Criteria:

• Inability to comply with protocol-mandated hospitalization

• Pregnancy or breastfeeding, or intention of becoming pregnant during the study orwithin 5 months after the final dose of cevostamab or tocilizumab or within 3 monthsafter the last dose of tocilizumab (if applicable)

• Prior treatment with cevostamab or another agent with the same target

• Prior BCMA ADC or CAR-T Cohort: prior treatment with any T cell dependentbi-specific antibody (TDB) antibody including non BCMA targeting TDB

• Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC asanti-cancer therapy within 4 weeks before first study treatment, except for the useof non-myeloma therapy

• Prior treatment with systemic immunotherapeutic agents

• Prior treatment with CAR-T cell therapy within 12 weeks before first cevostamabinfusion

• Known treatment-related, immune-mediated adverse events associated with priorcheckpoint inhibitors

• Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any otheranti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter,prior to first study treatment

• Autologous stem cell transplantation (SCT) within 100 days prior to first studytreatment

• Prior allogeneic SCT

• Circulating plasma cell count exceeding 500/ microliter (µL) or 5% of the peripheralblood white cells

• Prior solid organ transplantation

• History of autoimmune disease

• History of confirmed progressive multifocal leukoencephalopathy

• History of severe allergic or anaphylactic reactions to mAb therapy

• Known history of amyloidosis

• Lesions in proximity of vital organs that may develop suddendecompensation/deterioration in the setting of a tumor flare

• History of other malignancy within 2 years prior to screening, except those withnegligible risk of metastasis or death, such as ductal carcinoma in situ notrequiring chemotherapy, appropriately treated carcinoma in situ of the cervix,non-melanoma skin carcinoma, low-grade, localized prostate cancer not requiringtreatment or appropriately treated Stage I uterine cancer

• Current or past history of central nervous system (CNS) disease, such as stroke,epilepsy, CNS vasculitis, neurodegenerative disease, or CNS involvement by MM

• Significant cardiovascular disease that may limit a potential participant's abilityto adequately respond to a cytokine release syndrome (CRS) event

• Symptomatic active pulmonary disease or requiring supplemental oxygen

• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infectionat study enrollment, or any major episode of infection requiring treatment with IV (intravenous) antimicrobials where the last dose of IV antimicrobial was givenwithin 14 days prior to first study treatment

• Active symptomatic COVID-19 infection at study enrollment or requiring treatmentwith IV antiviral where the last dose of IV antiviral treatment was given within 14days prior to first study treatment. Participants with active COVID-19 infectionmust have clinical recovery and two negative antigen tests at least 24 hours apartprior to first study treatment

• Positive and quantifiable Epstein-Barr virus (EBV) polymerase chain reaction (PCR)or cytomegalovirus (CMV) PCR prior to first study treatment

• Known or suspected chronic active EBV infection

• Known history of Grade >=3 CRS or immune effector cell-associated neurotoxicitysyndrome (ICANS) with prior bispecific therapies

• Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activationsyndrome (MAS)

• Recent major surgery within 4 weeks prior to first study treatment

• Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV)infection

• Acute or chronic hepatitis C virus (HCV) infection

• Known history of human immunodeficiency virus (HIV) seropositivity

• Administration of a live, attenuated vaccine within 4 weeks before first studytreatment or anticipation that such a live attenuated vaccine will be requiredduring the study

• Treatment with systemic immunosuppressive medications, with the exception ofcorticosteroid treatment <= 10 mg/day prednisone or equivalent, within 2 weeks priorto first study treatment

• History of illicit drug or alcohol abuse within 12 months prior to screening, in theinvestigator's judgment

• Any medical condition or abnormality in clinical laboratory tests that, in theinvestigator's judgment, precludes the participant's safe participation in andcompletion of the study, or which could affect compliance with the protocol orinterpretation of results